SMT announces the start of S-Flex Registry in Netherland, the second in series after the successful completion of S-Flex UK registry

The study plans to enroll 1000 patients across 8 centers in Netherland with an aim to evaluate the safety and clinical performance of Supraflex, Sirolimus-Eluting Coronary Stent System in the global market

Mumbai / Netherlands, UK, 4th June 2018 – SMT (Sahajanand Medical Technologies Pvt. Ltd.), India's largest manufacturer of cardiovascular medical stents, announced the start of its S-flex Netherlands Registry today. The Netherland registry is the second in series post the successful completion of the UK registry early this year. Proudly moving ahead in the global market, SMT plans to enrol 1000 patients across 8 centres in Netherland with an aim to evaluate the safety & efficacy of Supraflex (DES) in real world all comer patient population requiring coronary intervention.

Dr A.J.J Ijsselmuiden, principal investigator from Amphia hospital, Breda, Netherland will be at the helm of the study. The enrolment process has already received a positive response with the admission of its 1st patient on 27th February 2018 at Amphia hospital, Breda. Currently, four out of the eight centres have already started the enrolment process.

Mr. Gaurav Goel, Head-Western Europe at SMT said "We believe ultrathin 60-micron struts, bio-degradable polymer and proven anti proliferative drug are the intrinsic elements to superior performance of Supraflex. This increases our confidence and we are sure that this study will replicate fantastic results of S-Flex UK registry in heart land Europe and will further complement vast clinical data of over 14,000 patients of SMT Family of DES."

Mr. Piyush Savalia, Sr. V.P. Marketing & Clinical Trial, SMT said, "SMT is always committed to deliver better clinical outcomes through our range of ultrathin biodegradable polymer DES. At present our Supraflex stent has delivered better patient outcome across countries. It has superseded wide spectrum of clinical parameters through various clinical studies. We are confident that our Netherland S Flex study will produce positive and excellent clinical outcomes that physicians expect from a next generation DES."

About Supraflex (Designed for Distal Delivery)
The CE-approved Supraflex, new biodegradable polymer-coated sirolimus-eluting stent (SES) is designed using an ultrathin (60µm) cobalt–chromium (Co–Cr) stent platform with a highly flexible 'S-link', which would enhance the deliverability of the stent, particularly in complex and challenging lesions. Clinical trial programme on Supra family of products has covered more than 12000 patients across the world till date.

About SMT (Sahajanand Medical Technologies)
SMT (Sahajanand Medical Technologies) a leading medical devices company specializing in the provision of life-changing vascular solutions. SMT offers an extensive portfolio of products that set industry benchmarks in vascular intervention by being the 1st company in the world to receive CE approval for DES with biodegradable polymer. Other distinguished 'benefactio' include ultrathin (60µm) lowest strut thickness for all the DES options offered by the company. Company has global presence with its footprints in more than 65 countries.